US8241664 — Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
Method of Use · Assigned to Clarus Therapeutics Inc · Expires 2029-03-29 · 3y remaining
What this patent protects
This patent protects a method of using a drug delivery system for oral administration of hydrophobic drugs, such as testosterone and its esters, to treat hormone deficiency or male contraception.
USPTO Abstract
A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.
Drugs covered by this patent
- Aveed (TESTOSTERONE UNDECANOATE) · Marius
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2506 |
— | Aveed |
U-2506 |
— | Aveed |
U-2506 |
— | Aveed |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.